|
Oct 15
|
Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
|
|
Jul 26
|
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
|
|
Jul 18
|
Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
|
|
Jan 10
|
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
|
|
Dec 2
|
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
|
|
Jul 12
|
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
|